Fig. 2: SRN promotes osteoclastogenesis in vitro.
From: Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone
A Western blotting analysis to validate SRGN knockdown in GCTB-1 and GCTB-19. B, C Osteoclast quantification (B) and representative images (C) in mouse primary bone marrow (BM) and RAW264.7 cultured in DMEM medium or conditioned media (CM) of GCTB-1 with or without SRGN knockdown in osteoclastogenesis assays. D, E Osteoclast quantification (D) and representative images (E) in mouse primary bone marrow and RAW264.7 cultured in DMEM medium or CM of GCTB-19 with or without SRGN knockdown in osteoclastogenesis assays. F Western blotting analysis to validate SRGN overexpression in hFOB1.19. G, H Osteoclast quantification (G) and representative images (H) in mouse primary bone marrow and RAW264.7 cultured in DMEM medium or CM of hFOB1.19 with or without SRGN overexpression in osteoclastogenesis assays. I, J Osteoclast quantification (I) and representative images (J) in mouse primary bone marrow and RAW264.7 treated with or without human recombinant SRGN protein (25 ng/mL) in osteoclastogenesis assays. Scale bar, 100 μm. Arrows point to giant osteoclast cells (C, E, H, J). P values were obtained by two-tailed unpaired t test (B, D, G, I). Bar graphs are shown as mean ± s.d.
